Symposium review: high altitude travel with pulmonary vascular disease
The Journal of Physiology · 2024
DOI: 10.1113/jp284585 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Physiology, 2024. Verfasst von Anna Titz und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Altitude, Hypertension, Pulmonary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are the main precapillary forms of pulmonary hypertension (PH) summarized as pulmonary vascular diseases (PVD). PVDs are characterized by exertional dyspnoea and oxygen desaturation, and reduced quality of life and survival. Medical therapies improve life expectancy and physical performance of PVD patients, of whom many wish to participate in professional work and recreational activities including traveling to high altitude. The exposure to the hypobaric hypoxic environment of mountain regions incurs the risk of high altitude adverse events (AE HA ) due to severe hypoxaemia exacerbating symptoms and further increase in pulmonary artery pressure, which may lead to right heart decompensation. Recent prospective and randomized trials show that altitude‐induced hypoxaemia, pulmonary haemodynamic changes and impairment of exercise performance in PVD patients are in the range found in healthy people. The vast majority of optimally treated stable PVD patients who do not require long‐term oxygen therapy at low altitude can tolerate short‐term exposure to moderate altitudes up to 2500 m. PVD patients that reveal persistent severe resting hypoxaemia ( 30 min) at 2500 m respond well to supplemental oxygen therapy. Although there are no accurate predictors for AE HA , PVD patients with unfavourable risk profiles at low altitude, such as higher WHO functional class, lower exercise capacity with more pronounced exercise‐induced desaturation and more severely impaired haemodynamics, are at increased risk of AE HA . Therefore, doctors with experience in PVD and high‐altitude medicine should counsel PVD patients before any high‐altitude sojourn. This review aims to summarize recent literature and clinical recommendations about PVD patients travelling to high altitude. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University Hospital of Zurich, Zurich, Switzerland.
- University of Zurich, Zurich, Switzerland.
ORCID-Profile: Anna Titz, Simon Schneider, Julian Mueller, Mona Lichtblau, Silvia Ulrich
Zitieren
APA
Titz, A., Schneider, S., Mueller, J., Mayer, L., Lichtblau, M., & Ulrich, S. (2024). Symposium review: high altitude travel with pulmonary vascular disease. The Journal of Physiology. https://doi.org/10.1113/jp284585
Vancouver
Titz A, Schneider S, Mueller J, Mayer L, Lichtblau M, Ulrich S. Symposium review: high altitude travel with pulmonary vascular disease. The Journal of Physiology. 2024. doi:10.1113/jp284585
BibTeX
@article{Titz2024,
author = {Titz, Anna and Schneider, Simon and Mueller, Julian and Mayer, Laura and Lichtblau, Mona and Ulrich, Silvia},
title = {Symposium review: high altitude travel with pulmonary vascular disease},
journal = {The Journal of Physiology},
year = {2024},
doi = {10.1113/jp284585}
}
EUVIMED